A phase I study of AIT-082 in healthy elderly volunteers

Michael Grundman, Martin Farlow, Guerry Peavy, Hyun T. Kim, Edmund Capparelli, Arlan N. Schultz, David P. Salmon, Steven H. Ferris, Richard Mohs, Ronald G. Thomas, Kimberly Schafer, Karen Campbell, Ann Hake, Barbara Schoos, Leon J. Thal

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A Phase I, double-blind, placebo-controlled, single-dose, escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics, Inc.) was conducted in healthy elderly volunteers. This trial was designed to evaluate single-dose safety, tolerability, and pharmacokinetics. Potential cognitive domains that might benefit from AIT-082 were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease (AD). Preclinical studies indicate that AIT-082 has memory-enhancing properties, stimulates neuritogenesis, and upregulates neurotrophic factors. Subjects received a single oral dose of AIT-082 or placebo on a weekly basis for 5 wk. All patients received a placebo dose at baseline. Six subjects received increasing doses of AIT-082 over the next 4 wk at doses of 0.6, 2.0, 6.0, and 20.0 mg of AIT-082 per kilogram of body weight. Two subjects received placebo throughout the trial. Nine subjects were recruited. One subject was withdrawn after the third treatment visit owing to poor venous access. There were no serious adverse events. The drug was well-tolerated. The time to peak drug concentration was approx 85 min with an elimination half-life of approx 17.6 h. Performance on the Number Comparison, Symbol Digit, and Trails A tests improved with AIT-082 dosing compared to baseline (placebo). In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated.

Original languageEnglish (US)
Pages (from-to)283-293
Number of pages11
JournalJournal of Molecular Neuroscience
Volume18
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Healthy Volunteers
Placebos
Half-Life
4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid
Safety
Pharmacokinetics
Nerve Growth Factors
Pharmaceutical Preparations
Alzheimer Disease
Up-Regulation
Body Weight
Derivatives
Data storage equipment
Therapeutics

Keywords

  • AIT-082
  • Clinical trial
  • Neotrofin
  • Pharmacokinetics
  • Phase I

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry
  • Genetics

Cite this

Grundman, M., Farlow, M., Peavy, G., Kim, H. T., Capparelli, E., Schultz, A. N., ... Thal, L. J. (2002). A phase I study of AIT-082 in healthy elderly volunteers. Journal of Molecular Neuroscience, 18(3), 283-293. https://doi.org/10.1385/JMN:18:3:283

A phase I study of AIT-082 in healthy elderly volunteers. / Grundman, Michael; Farlow, Martin; Peavy, Guerry; Kim, Hyun T.; Capparelli, Edmund; Schultz, Arlan N.; Salmon, David P.; Ferris, Steven H.; Mohs, Richard; Thomas, Ronald G.; Schafer, Kimberly; Campbell, Karen; Hake, Ann; Schoos, Barbara; Thal, Leon J.

In: Journal of Molecular Neuroscience, Vol. 18, No. 3, 2002, p. 283-293.

Research output: Contribution to journalArticle

Grundman, M, Farlow, M, Peavy, G, Kim, HT, Capparelli, E, Schultz, AN, Salmon, DP, Ferris, SH, Mohs, R, Thomas, RG, Schafer, K, Campbell, K, Hake, A, Schoos, B & Thal, LJ 2002, 'A phase I study of AIT-082 in healthy elderly volunteers', Journal of Molecular Neuroscience, vol. 18, no. 3, pp. 283-293. https://doi.org/10.1385/JMN:18:3:283
Grundman, Michael ; Farlow, Martin ; Peavy, Guerry ; Kim, Hyun T. ; Capparelli, Edmund ; Schultz, Arlan N. ; Salmon, David P. ; Ferris, Steven H. ; Mohs, Richard ; Thomas, Ronald G. ; Schafer, Kimberly ; Campbell, Karen ; Hake, Ann ; Schoos, Barbara ; Thal, Leon J. / A phase I study of AIT-082 in healthy elderly volunteers. In: Journal of Molecular Neuroscience. 2002 ; Vol. 18, No. 3. pp. 283-293.
@article{acaf50e99023496a9a19767ddace6e34,
title = "A phase I study of AIT-082 in healthy elderly volunteers",
abstract = "A Phase I, double-blind, placebo-controlled, single-dose, escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics, Inc.) was conducted in healthy elderly volunteers. This trial was designed to evaluate single-dose safety, tolerability, and pharmacokinetics. Potential cognitive domains that might benefit from AIT-082 were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease (AD). Preclinical studies indicate that AIT-082 has memory-enhancing properties, stimulates neuritogenesis, and upregulates neurotrophic factors. Subjects received a single oral dose of AIT-082 or placebo on a weekly basis for 5 wk. All patients received a placebo dose at baseline. Six subjects received increasing doses of AIT-082 over the next 4 wk at doses of 0.6, 2.0, 6.0, and 20.0 mg of AIT-082 per kilogram of body weight. Two subjects received placebo throughout the trial. Nine subjects were recruited. One subject was withdrawn after the third treatment visit owing to poor venous access. There were no serious adverse events. The drug was well-tolerated. The time to peak drug concentration was approx 85 min with an elimination half-life of approx 17.6 h. Performance on the Number Comparison, Symbol Digit, and Trails A tests improved with AIT-082 dosing compared to baseline (placebo). In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated.",
keywords = "AIT-082, Clinical trial, Neotrofin, Pharmacokinetics, Phase I",
author = "Michael Grundman and Martin Farlow and Guerry Peavy and Kim, {Hyun T.} and Edmund Capparelli and Schultz, {Arlan N.} and Salmon, {David P.} and Ferris, {Steven H.} and Richard Mohs and Thomas, {Ronald G.} and Kimberly Schafer and Karen Campbell and Ann Hake and Barbara Schoos and Thal, {Leon J.}",
year = "2002",
doi = "10.1385/JMN:18:3:283",
language = "English (US)",
volume = "18",
pages = "283--293",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - A phase I study of AIT-082 in healthy elderly volunteers

AU - Grundman, Michael

AU - Farlow, Martin

AU - Peavy, Guerry

AU - Kim, Hyun T.

AU - Capparelli, Edmund

AU - Schultz, Arlan N.

AU - Salmon, David P.

AU - Ferris, Steven H.

AU - Mohs, Richard

AU - Thomas, Ronald G.

AU - Schafer, Kimberly

AU - Campbell, Karen

AU - Hake, Ann

AU - Schoos, Barbara

AU - Thal, Leon J.

PY - 2002

Y1 - 2002

N2 - A Phase I, double-blind, placebo-controlled, single-dose, escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics, Inc.) was conducted in healthy elderly volunteers. This trial was designed to evaluate single-dose safety, tolerability, and pharmacokinetics. Potential cognitive domains that might benefit from AIT-082 were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease (AD). Preclinical studies indicate that AIT-082 has memory-enhancing properties, stimulates neuritogenesis, and upregulates neurotrophic factors. Subjects received a single oral dose of AIT-082 or placebo on a weekly basis for 5 wk. All patients received a placebo dose at baseline. Six subjects received increasing doses of AIT-082 over the next 4 wk at doses of 0.6, 2.0, 6.0, and 20.0 mg of AIT-082 per kilogram of body weight. Two subjects received placebo throughout the trial. Nine subjects were recruited. One subject was withdrawn after the third treatment visit owing to poor venous access. There were no serious adverse events. The drug was well-tolerated. The time to peak drug concentration was approx 85 min with an elimination half-life of approx 17.6 h. Performance on the Number Comparison, Symbol Digit, and Trails A tests improved with AIT-082 dosing compared to baseline (placebo). In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated.

AB - A Phase I, double-blind, placebo-controlled, single-dose, escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics, Inc.) was conducted in healthy elderly volunteers. This trial was designed to evaluate single-dose safety, tolerability, and pharmacokinetics. Potential cognitive domains that might benefit from AIT-082 were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease (AD). Preclinical studies indicate that AIT-082 has memory-enhancing properties, stimulates neuritogenesis, and upregulates neurotrophic factors. Subjects received a single oral dose of AIT-082 or placebo on a weekly basis for 5 wk. All patients received a placebo dose at baseline. Six subjects received increasing doses of AIT-082 over the next 4 wk at doses of 0.6, 2.0, 6.0, and 20.0 mg of AIT-082 per kilogram of body weight. Two subjects received placebo throughout the trial. Nine subjects were recruited. One subject was withdrawn after the third treatment visit owing to poor venous access. There were no serious adverse events. The drug was well-tolerated. The time to peak drug concentration was approx 85 min with an elimination half-life of approx 17.6 h. Performance on the Number Comparison, Symbol Digit, and Trails A tests improved with AIT-082 dosing compared to baseline (placebo). In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated.

KW - AIT-082

KW - Clinical trial

KW - Neotrofin

KW - Pharmacokinetics

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0036014124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036014124&partnerID=8YFLogxK

U2 - 10.1385/JMN:18:3:283

DO - 10.1385/JMN:18:3:283

M3 - Article

VL - 18

SP - 283

EP - 293

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 3

ER -